Commitments and Contingencies (Additional Information) (Details)
$ / shares in Units, $ in Thousands, ₩ in Billions |
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
|
Jun. 24, 2026
USD ($)
Bcfe
$ / shares
|
May 11, 2026
USD ($)
$ / shares
shares
|
May 04, 2026
USD ($)
$ / shares
shares
|
Apr. 02, 2026
USD ($)
|
Mar. 11, 2026
USD ($)
|
Aug. 20, 2025
USD ($)
$ / shares
shares
|
Nov. 30, 2025
USD ($)
|
Feb. 28, 2013 |
Jun. 30, 2026
USD ($)
CryptoUnits
$ / shares
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2026
USD ($)
CryptoUnits
$ / shares
shares
|
Jun. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
$ / shares
|
Jun. 30, 2026
KRW (₩)
CryptoUnits
|
May 22, 2026
$ / shares
|
Apr. 26, 2026
USD ($)
|
Mar. 02, 2026
$ / shares
|
Jan. 29, 2026
USD ($)
$ / shares
shares
|
Aug. 31, 2025
USD ($)
|
Aug. 17, 2025
USD ($)
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock Share Price | $ / shares |
|
|
|
|
|
|
|
|
$ 630
|
|
$ 630
|
|
|
|
|
|
|
|
|
|
| Royalty expenses |
|
|
|
|
|
|
|
|
$ 0
|
$ 100
|
$ 0
|
$ 100
|
|
|
|
|
|
|
|
|
| Prepayment costs |
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finance lease liabilities |
|
|
|
|
|
|
|
|
$ 0
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
| Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] |
|
|
|
|
|
|
|
|
Derivative Liability, Noncurrent
|
|
Derivative Liability, Noncurrent
|
|
|
Derivative Liability, Noncurrent
|
|
|
|
|
|
|
| Lease Expense |
|
|
|
|
|
|
|
|
$ 1,100
|
200
|
$ 2,300
|
500
|
|
|
|
|
|
|
|
|
| Implementation fee related to sales |
|
|
|
|
|
|
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
| Implementation fee of First Year |
|
|
|
|
|
|
|
|
|
|
1,200
|
|
|
|
|
|
|
|
|
|
| Implementation fee of Second And Third Year |
|
|
|
|
|
|
|
|
|
|
1,300
|
|
|
|
|
|
|
|
|
|
| Non-refundable deposit |
|
|
|
|
|
|
$ 2,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Impairment Loss |
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
$ 2,500
|
|
|
|
|
|
|
|
| Data Vault Units |
837
|
|
|
|
|
|
|
|
252,451,631
|
|
252,451,631
|
|
|
252,451,631
|
|
|
|
|
|
|
| Number of Common Stock Shares Issued | shares |
|
|
|
|
|
|
|
|
|
|
32,135,626
|
|
|
|
|
|
|
|
|
|
| Price per share (in Dollars per share) | $ / shares |
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, par value | $ / shares |
|
|
|
|
|
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
$ 0.0001
|
|
$ 0.0001
|
|
$ 0.68
|
|
|
|
| Sale of Stock Percentage of Ownership after Transaction |
|
|
82.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Upfront Payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 120,000
|
|
|
|
|
| Initial Payment |
$ 30,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Remaining Payment |
20,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Datavault Bitcoin [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment for Crypto Asset |
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| WorldXchain [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of Common Stock Shares Issued | shares |
|
25,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share (in Dollars per share) | $ / shares |
|
$ 0.00001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NeuroBiogen Co., Ltd. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Upfront Fee, Assignment and License Agreement | ₩ |
|
|
|
|
|
|
|
|
|
|
|
|
|
₩ 1.5
|
|
|
|
|
|
|
| Upfront Fee due date |
|
|
|
|
|
|
|
|
|
|
May 31, 2025
|
|
|
|
|
|
|
|
|
|
| Former Employee [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Agreement settlement payment |
|
|
|
|
|
|
|
|
|
|
$ 3,500
|
|
|
|
|
|
|
|
|
|
| Former Employee One[Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Agreement settlement payment |
|
|
|
|
|
|
|
|
|
|
$ 2,500
|
|
|
|
|
|
|
|
|
|
| Mr. Mack [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Payment for attorneys fees |
|
|
|
$ 5,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Definitive Agreement With Phoenix Asia Holdings Limited |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of Common Stock Shares Issued | shares |
|
|
100,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share (in Dollars per share) | $ / shares |
|
|
$ 10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, par value | $ / shares |
|
|
$ 0.00001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of common shares |
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vivasor Commitment to Purchase EcoExtract Common Stock [Member] | EcoExtract [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of Common Stock Shares Issued | shares |
|
25,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate purchase price |
|
$ 1,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share (in Dollars per share) | $ / shares |
|
$ 0.039216
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phoenix Asia Holdings Limited [Member] | Definitive Agreement With Phoenix Asia Holdings Limited |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of Ownership Equity Interest Rate |
|
|
100.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock Share Price | $ / shares |
|
|
|
|
|
$ 16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Investor agreed to purchase Share | shares |
|
|
|
|
|
1,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate purchase price |
|
|
|
|
|
$ 20,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Probudur [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage on net sale |
|
|
|
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
|
|
| Envelta [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage on net sale |
|
|
|
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
|
|
| Epoladerm [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage on net sale |
|
|
|
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
|
|
| Product Development Agreement [Member] | Developers [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expenses |
|
|
|
|
|
|
|
|
$ 1,000
|
1,600
|
$ 1,900
|
2,300
|
|
|
|
|
|
|
|
|
| Accrued royalty payables |
|
|
|
|
|
|
|
|
1,600
|
|
$ 1,600
|
|
$ 2,100
|
|
|
|
|
|
|
|
| Agreement maturity date |
|
|
|
|
|
|
|
Oct. 02, 2028
|
|
|
|
|
|
|
|
|
|
|
|
|
| Agreement maturity renewal description |
|
|
|
|
|
|
|
|
|
|
The Product Development Agreement will renew automatically for subsequent successive one-year renewal periods unless Scilex Pharma or the Developers terminate it upon six-months’ written notice.
|
|
|
|
|
|
|
|
|
|
| Product Development Agreement [Member] | Developers [Member] | Minimum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty payment percentage related to future years |
|
|
|
|
|
|
|
|
|
|
25.00%
|
|
|
|
|
|
|
|
|
|
| Product Development Agreement [Member] | Developers [Member] | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty payment percentage related to future years |
|
|
|
|
|
|
|
|
|
|
35.00%
|
|
|
|
|
|
|
|
|
|
| Product Development Agreement [Member] | Scilex Pharma [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty expenses |
|
|
|
|
|
|
|
|
$ 1,200
|
$ 600
|
$ 2,400
|
$ 1,900
|
|
|
|
|
|
|
|
|
| Non-cancelable Lease Agreements [Member] | Minimum | Research and Development Facilities [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating lease, remaining lease term |
|
|
|
|
|
|
|
|
10 years 2 months 12 days
|
|
10 years 2 months 12 days
|
|
|
10 years 2 months 12 days
|
|
|
|
|
|
|
| Operating lease, lease term |
|
|
|
|
|
|
|
|
1 year
|
|
1 year
|
|
|
1 year
|
|
|
|
|
|
|
| Non-cancelable Lease Agreements [Member] | Maximum | Research and Development Facilities [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating lease, lease term |
|
|
|
|
|
|
|
|
13 years
|
|
13 years
|
|
|
13 years
|
|
|
|
|
|
|
| Investment Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Contingent consideration, liability |
|
|
|
|
|
|
|
|
$ 1,500
|
|
$ 1,500
|
|
1,000
|
|
|
|
|
|
$ 2,500
|
|
| Investment Agreement | PA OPS Investor LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Contingent consideration, liability |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,500
|
| Long Term Commitment Amount |
|
|
|
|
|
|
|
|
|
|
$ 2,500
|
|
$ 2,500
|
|
|
|
|
|
|
|
| Loan interest rate |
|
|
|
|
|
|
|
|
|
|
4.03%
|
|
4.03%
|
|
|
|
|
|
|
|
| Common Stock Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitments and Contingencies [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock Share Price | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.14247
|
|
|
| Common Stock Share Purchases | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
193,021,436
|
|
|
| Payments for Purchase of Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 27,500
|
|
|